智飞生物(300122) - 2023 Q1 - 季度财报

Financial Performance - The company's revenue for Q1 2023 reached ¥11,172,773,125.45, representing a 26.37% increase compared to ¥8,841,150,250.19 in the same period last year[4] - Net profit attributable to shareholders was ¥2,032,024,553.16, a 5.68% increase from ¥1,922,756,886.80 year-on-year[4] - Basic earnings per share for Q1 2023 was ¥1.2700, reflecting a 5.68% increase from ¥1.2017 in the same quarter last year[4] - Total operating revenue for Q1 2023 reached CNY 11,172,773,125.45, a significant increase from CNY 8,841,150,250.19 in Q1 2022, representing a growth of approximately 26.9%[19] - Net profit for Q1 2023 was CNY 2,032,024,553.16, compared to CNY 1,922,756,886.80 in the same period last year, reflecting an increase of about 5.7%[20] - The company reported a total comprehensive income of CNY 2,032,024,553.16 for Q1 2023, compared to CNY 1,922,756,886.80 in the same period last year, showing an increase of about 5.7%[21] Cash Flow and Liquidity - The net cash flow from operating activities improved significantly, with a net outflow of ¥1,040,028,831.23, a 68.64% reduction from the previous year's outflow of ¥3,316,743,954.40[11] - The company reported a significant increase in cash and cash equivalents of ¥176,160,972.80, a 107.60% improvement compared to a significant decrease in the previous year[11] - The cash inflow from financing activities totaled 2,866,915,531.74 CNY, an increase from 1,720,866,416.95 CNY in the prior period[24] - The net cash flow from financing activities was 1,491,721,904.16 CNY, compared to 1,412,329,711.67 CNY in the previous period[24] - The cash and cash equivalents at the end of the period amounted to 2,791,849,824.14 CNY, up from 1,961,452,199.09 CNY in the prior period[24] - The company experienced a net increase in cash and cash equivalents of 176,160,972.80 CNY, contrasting with a decrease of -2,318,248,546.21 CNY in the previous period[24] Assets and Liabilities - Total assets increased by 13.78% to ¥43,242,428,755.31 from ¥38,003,733,941.95 at the end of the previous year[5] - The total assets of the company increased to CNY 43,242,428,755.31 from CNY 38,003,733,941.95 at the beginning of the year, marking a growth of about 13.5%[18] - Total current liabilities increased to CNY 16.36 billion from CNY 13.23 billion, which is an increase of approximately 23.8%[17] - The company's total liabilities reached CNY 16.97 billion, compared to CNY 13.77 billion at the beginning of the year, indicating a growth of approximately 23.9%[17] Research and Development - The company's R&D expenses rose to ¥213,960,021.59, marking a 32.98% increase compared to ¥160,890,893.91 in the prior year[10] - Research and development expenses amounted to CNY 213,960,021.59, up from CNY 160,890,893.91 in Q1 2022, indicating a year-over-year increase of approximately 33%[20] Equity and Shareholder Information - The total equity attributable to shareholders increased by 8.38% to ¥26,268,237,162.33 from ¥24,236,212,609.17 at the end of the previous year[5] - The company's total equity attributable to shareholders reached CNY 26,268,237,162.33, up from CNY 24,236,212,609.17 at the beginning of the year, indicating a growth of approximately 8.4%[18] Employee Compensation and Engagement - The company reported a significant increase in employee compensation liabilities, which decreased to CNY 36.53 million from CNY 182.21 million, indicating a reduction of approximately 80%[17] - The company is actively involved in employee stock ownership plans, with specific funds allocated for this purpose, indicating a strategic focus on employee engagement and retention[14] Other Financial Metrics - The weighted average return on equity decreased to 8.05%, down by 2.28% from 10.33% in the same period last year[4] - Tax expenses for Q1 2023 were CNY 360,264,719.19, slightly higher than CNY 340,224,600.65 in Q1 2022, reflecting an increase of approximately 5.9%[20] - The total operating costs for Q1 2023 were CNY 8,596,876,197.85, up from CNY 6,503,327,142.16 in the same period last year, reflecting an increase of about 32.4%[19] Audit Status - The first quarter report was not audited[25]